AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Characterizing Synaptic Density in Treatment Resistant Depression

Recruitingn/aAges 25 Years - 65 YearsAllUnity Health Toronto
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to better understand how certain brain systems work in people with depression, especially in those whose symptoms have not improved with antidepressant treatments. The investigators are particularly interested in synaptic density, which helps to understand how different parts of the brain communicate with one another. Synaptic density levels have implications on overall brain function and cognition. By comparing brain function in people with treatment-resistant depression, people with treatment-responsive depression, and healthy controls, investigators hope to better understand why some individuals do not respond to antidepressants. This research may help guide the development of more effective treatments in the future.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Key inclusion criteria for the MDD patients: * DSM-5 criteria for a Major Depressive Episode (MDE) within a MDD, confirmed through MINI diagnosis (Sheehan et al, 2015) * Age between 25 and 65 years * Hamilton Depression Rating Scale - 17 item (HRSD-17; Hamilton, 1960) \> 14 (moderate to severe symptoms) * Free of psychotropic medications (with the exception of SSRIs or SNRIs) for at least 5 half-lives before PET scanning per investigator discretion, after which an insignificant amount of drug is circulating through the body and accessing the brain. This determination will be based on self-report from the participant of when their last dose was. Use of benzodiazepines (except for diazepam) or sedative hypnotics (e.g. zopiclone) is allowable, but the last dose must be at least 72 hours prior to scanning. * Ability to undergo MRI scanning (absence of metal, pacemakers, etc.) * For non-resistant patients: Previous history of response to an antidepressant, in order to increase signal to noise between resistant and non-resistant patients Key inclusion criteria for the Healthy Controls: * Ages between 25 and 65 years * Ability to undergo MRI scanning (absence of metal, pacemakers, etc.) Exclusion Criteria: Key exclusion criteria for the MDD patients: * Pregnancy/lactation * Medical condition requiring immediate investigation or treatment * Recent (\< 6 months)/current history of drug abuse/dependence * Lifetime history of psychosis, other Axis I comorbidities are allowable * Use of any psychotropic use within 5 half-lives before the PET scanning, with the exception of SSRIs and SNRIs * For non-resistant patients: Failure of \> 2 antidepressant treatments of adequate dose and duration for current MDE. Key exclusion criteria for the Healthy Controls: * Pregnancy/lactation * Medical condition requiring immediate investigation or treatment * Lifetime history of any psychiatric disorder * Lifetime history of receiving an antidepressant
๐Ÿ’Š

What it tests

  • PET scans
๐Ÿ“

Where

1 site
Unity Health Toronto
Toronto, Canada
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy